Evidence map›Paper›PMID 40325349›Full record

ArticleJournal of neuroendocrinology2025

The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study.

Kazhan Mollazadegan, Johan Botling, Britt Skogseid, Barbro Eriksson, Lovisa Falkman, Liang Zhang, Ieva Lase, Staffan Welin, Anders Sundin, Joakim Crona

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroendocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03130205 (Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03130205 unknown statusnot on this map

Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours

TypeobservationalSponsorUppsala UniversityRan2017 to 2022Enrolled30ConditionsNeuroendocrine TumorsArmsCore Needle Biopsy, Computed Tomography, 18F-FDG-PET, Phlebotomy, Molecular genetic analysis
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kazhan MollazadeganDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-9423-8970
Johan BotlingDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Britt SkogseidDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Barbro ErikssonDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Lovisa FalkmanDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Liang ZhangDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-8448-6754
Ieva LaseDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-2153-8013
Staffan WelinDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Anders SundinDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Joakim CronaDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.

Funding

Åke Wibergs StiftelseBengt Ihres FondCancerfondenEuropean Neuroendocrine Tumor Society Young InvestigatorLennart Glans StiftelseLions cancerforskningsfondNordic Neuroendocrine Tumor GroupRegion Uppsala ALFTorsten och Ragnar Söderbergs Stiftelse
6 · The paper itself

Abstract

The biology of metastatic pancreatic neuroendocrine tumors (panNET) may alter over time. It remains to be defined if, how, and when this patient group should be recommended to re-evaluate the characteristics of their disease. This prospective single-center, longitudinal cohort study at Uppsala University Hospital, Sweden (NCT03130205), included metastatic panNET patients with progressive disease to participate in a standardized re-characterization protocol: clinical and biochemical analyses, core-needle biopsy, and dual-positron emission tomography/computed tomography (PET/CT) (

Indexed as

Neuroendocrine TumorsPancreatic NeoplasmsAdultAgedDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedNeoplasm MetastasisPositron Emission Tomography Computed TomographyProspective StudiesSwedenhormonesKi‐67pancreatic neuroendocrine tumorPET/CTre‐characterization

Identifiers

PMID40325349
PMCPMC12358203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.